Search

everythinglearnresearchcommunity

for

Search:↓

Exosomes, cetirizine, melatonin, latanoprost, and caffeine are discussed as potential hair loss treatments. There is skepticism about the effectiveness of exosomes, especially in topical form, but some users report positive results.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

The user started a hair care routine using 0.5mg finasteride daily, 2ml of 5% minoxidil, and 4.5mg of cetirizine topically to address hair loss. They plan to provide updates and are also interested in cetirizine's potential to reduce scalp itching and redness due to its anti-inflammatory properties.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

User asks about Pyrilutamide release in Europe, specifically Germany, and considers importing it from China. No specific treatments mentioned.

User experienced hair thickening with pyri but also side effects like reduced sex drive. Stopping pyri and returning to CB restored sex drive, suggesting pyri may go systemic or be incorrectly formulated.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

Creatine does not cause hair loss, but it may accelerate hair loss in those predisposed to male pattern baldness. Finasteride users report mixed experiences with creatine, with some noticing no change and others experiencing increased shedding.

A 21-year-old male managed to control his hair loss using Nizoral, RU58841, and finasteride, but experienced increased scalp itchiness after starting creatine, which subsided upon stopping creatine. Users shared mixed experiences on whether creatine affects hair loss, with some reporting negative effects and others seeing no change or defending its benefits.

The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.

User has seborrhoeic dermatitis causing hair loss. They are using Ketoconazole shampoo and may use selenium sulfide shampoo.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

Glycine may upregulate 5AR, potentially affecting hair. Users suggest using Finasteride to manage hair loss concerns.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

Pyrilutamide from Ligand Chem was used by several individuals to address hair loss, with mixed results and no significant side effects reported. Some users switched to Minoxidil Max for better value, while others noted no hair growth or only a reduction in shedding.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

Minoxidil can cause dark circles and skin issues, and users suggest reducing dosage or switching to foam. Supplements like vitamin C, glycine, and MSM may help with collagen production to reduce these side effects.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

Creatine use is linked to increased hair shedding for some, especially those with DHT sensitivity, but experiences vary. Some users manage hair loss with treatments like finasteride, minoxidil, or dutasteride, while others stop creatine to reduce shedding.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

Creatine does not cause or worsen hair loss, despite some anecdotal reports of hair thinning. The discussion emphasizes that these reports are not supported by scientific evidence.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.